Literature DB >> 25201087

Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).

Bruno Guedes Baldi1, Mariana Sponholz Araujo, Carolina Salim Gonçalves Freitas, Gustavo Borges da Silva Teles, Ronaldo Adib Kairalla, Olívia Meira Dias, Daniel Antunes Silva Pereira, Suzana Pinheiro Pimenta, Carlos Roberto Ribeiro Carvalho.   

Abstract

PURPOSE: Although computed tomography (CT) has been used previously to assess disease severity in lymphangioleiomyomatosis (LAM), the associations between the extent of pulmonary cysts on CT and six-minute walk test (6MWT), matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF-D) are not well established. We performed a cross-sectional study to quantify the extent of pulmonary cysts in CT and to establish their correlations with pulmonary function tests (PFTs), 6MWT results, including a composite index (desaturation-distance ratio, DDR), and levels of VEGF-D and MMPs in LAM.
METHODS: Twenty-three LAM patients underwent CT scanning to automatically quantify the extent of pulmonary cysts and performed PFTs and 6MWT. Serum levels of MMP-2, MMP-9, and VEGF-D were also measured.
RESULTS: The severity of pulmonary cystic involvement was mild (the extent of cysts was 6.8 %) and correlated best with FEV1/FVC (r = -0.84), residual volume (r = 0.66), DLCO (r = -0.82), the DDR index (r = 0.77), and desaturation during the 6MWT (r = -0.81). There was a weak correlation with VEGF-D (r = 0.45), but no association was found with MMP-2 and MMP-9.
CONCLUSIONS: The severity of pulmonary cystic involvement was mild in this sample of LAM patients and correlated best with airway obstruction, air trapping, reduced DLCO, the DDR index, and desaturation during the 6MWT. Serum VEGF-D cannot be completely defined as a valuable marker of disease severity and there may be a mechanism independent of MMPs to explain the formation of pulmonary cysts.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201087     DOI: 10.1007/s00408-014-9641-2

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  31 in total

1.  Reference values for lung function tests. I. Static volumes.

Authors:  J A Neder; S Andreoni; A Castelo-Filho; L E Nery
Journal:  Braz J Med Biol Res       Date:  1999-06       Impact factor: 2.590

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  Six-minute walk test: reference values for healthy adults in Brazil.

Authors:  Maria Raquel Soaresa; Carlos Alberto de Castro Pereira
Journal:  J Bras Pneumol       Date:  2011 Sep-Oct       Impact factor: 2.624

4.  Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade.

Authors:  Suzana Pinheiro Pimenta; Bruno Guedes Baldi; Milena Marques Pagliarelli Acencio; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2011 Jul-Aug       Impact factor: 2.624

5.  Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis.

Authors:  Bruno G Baldi; André L P Albuquerque; Suzana P Pimenta; João M Salge; Ronaldo A Kairalla; Carlos R R Carvalho
Journal:  Am J Respir Crit Care Med       Date:  2012-06-14       Impact factor: 21.405

6.  Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score.

Authors:  K Matsui; M B Beasley; W K Nelson; P M Barnes; J Bechtle; R Falk; V J Ferrans; J Moss; W D Travis
Journal:  Am J Surg Pathol       Date:  2001-04       Impact factor: 6.394

7.  CT grading of lung disease in lymphangioleiomyomatosis.

Authors:  Jianhua Yao; Angelo M Taveira-DaSilva; Thomas V Colby; Joel Moss
Journal:  AJR Am J Roentgenol       Date:  2012-10       Impact factor: 3.959

8.  Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.

Authors:  R S Crausman; D A Lynch; R L Mortenson; T E King; C G Irvin; V A Hale; J D Newell
Journal:  Chest       Date:  1996-01       Impact factor: 9.410

9.  Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Mario P Stylianou; Carolyn J Hedin; Arnold S Kristof; Nilo A Avila; Antoinette Rabel; William D Travis; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2003-09-04       Impact factor: 21.405

10.  Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis.

Authors:  Vincent J Schmithorst; Talissa A Altes; Lisa R Young; David N Franz; John J Bissler; Francis X McCormack; Bernard J Dardzinski; Alan S Brody
Journal:  AJR Am J Roentgenol       Date:  2009-04       Impact factor: 3.959

View more
  7 in total

1.  Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.

Authors:  Alexandre Franco Amaral; Martina Rodrigues de Oliveira; Olívia Meira Dias; Fábio Eiji Arimura; Carolina Salim Gonçalves Freitas; Milena Marques Pagliarelli Acencio; Vanessa Adélia de Alvarenga; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho; Bruno Guedes Baldi
Journal:  Lung       Date:  2019-01-08       Impact factor: 2.584

Review 2.  Lymphangioleiomyomatosis: New Treatment Perspectives.

Authors:  Elżbieta Radzikowska
Journal:  Lung       Date:  2015-05-17       Impact factor: 2.584

3.  Oxygen desaturation during a 6-minute walk test as a predictor of maximal exercise-induced gas exchange abnormalities in sarcoidosis.

Authors:  Cecile Chenivesse; Sarah Boulanger; Carole Langlois; Lidwine Wemeau-Stervinou; Thierry Perez; Benoit Wallaert
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

4.  Immunohistological features related to functional impairment in lymphangioleiomyomatosis.

Authors:  Ellen Caroline Toledo do Nascimento; Bruno Guedes Baldi; Alessandro Wasum Mariani; Raquel Annoni; Ronaldo Adib Kairalla; Suzana Pinheiro Pimenta; Luiz Fernando Ferraz da Silva; Carlos Roberto Ribeiro Carvalho; Marisa Dolhnikoff
Journal:  Respir Res       Date:  2018-05-08

5.  Quantitative analysis of airway obstruction in lymphangioleiomyomatosis.

Authors:  Stijn E Verleden; Arno Vanstapel; Laurens De Sadeleer; Birgit Weynand; Matthieu Boone; Erik Verbeken; Davide Piloni; Dirk Van Raemdonck; Maximilian Ackermann; Danny D Jonigk; Johny Verschakelen; Wim A Wuyts
Journal:  Eur Respir J       Date:  2020-07-02       Impact factor: 16.671

6.  Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients.

Authors:  C Daccord; V Cottin; G Prévot; Y Uzunhan; J F Mornex; P Bonniaud; R Borie; A Briault; M A Collonge-Rame; B Crestani; G Devouassoux; O Freynet; A Gondouin; P A Hauss; C Khouatra; S Leroy; S Marchand-Adam; C Marquette; D Montani; J M Naccache; G Nadeau; N Poulalhon; M Reynaud-Gaubert; M Salaun; B Wallaert; J F Cordier; M Faouzi; R Lazor
Journal:  Orphanet J Rare Dis       Date:  2020-05-24       Impact factor: 4.123

7.  Quantitative assessment of pulmonary function in lymphangioleiomyomatosis patients using high-resolution computed tomography and pulmonary function tests.

Authors:  Zhiwen Ni; Thomas S C Ng; Jie Liu; Suidan Huang; Xiaoling Li; Xiaoyin Xu; Huai Chen
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.